# Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

> **NCT05373446** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SSD8432 300mg
- **DRUG:** SSD8432 750mg
- **DRUG:** SSD8432Placebo

## Key facts

- **NCT ID:** NCT05373446
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-20
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05373446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05373446, "Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05373446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*